India · Delayed Price · Currency is INR Beryl Drugs Statistics
Total Valuation
Beryl Drugs has a market cap or net worth of INR 116.65 million. The enterprise value is 138.32 million.
| Market Cap | 116.65M |
| Enterprise Value | 138.32M |
Important Dates
The last earnings date was Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beryl Drugs has 5.07 million shares outstanding. The number of shares has decreased by -2.80% in one year.
| Current Share Class | 5.07M |
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | -2.80% |
| Shares Change (QoQ) | -0.97% |
| Owned by Insiders (%) | 41.79% |
| Owned by Institutions (%) | n/a |
| Float | 2.95M |
Valuation Ratios
The trailing PE ratio is 18.39.
| PE Ratio | 18.39 |
| Forward PE | n/a |
| PS Ratio | 0.54 |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 3.20 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 22.15 |
| EV / Sales | 0.64 |
| EV / EBITDA | 5.22 |
| EV / EBIT | 12.65 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 0.92 |
| Debt / FCF | -13.97 |
| Interest Coverage | 3.58 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 7.19% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Beryl Drugs has paid 1.64 million in taxes.
| Income Tax | 1.64M |
| Effective Tax Rate | 20.76% |
Stock Price Statistics
The stock price has increased by +13.41% in the last 52 weeks. The beta is 0.06, so Beryl Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +13.41% |
| 50-Day Moving Average | 22.55 |
| 200-Day Moving Average | 22.16 |
| Relative Strength Index (RSI) | 53.20 |
| Average Volume (20 Days) | 2,269 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beryl Drugs had revenue of INR 215.51 million and earned 6.25 million in profits. Earnings per share was 1.25.
| Revenue | 215.51M |
| Gross Profit | 93.80M |
| Operating Income | 10.94M |
| Pretax Income | 7.88M |
| Net Income | 6.25M |
| EBITDA | 26.49M |
| EBIT | 10.94M |
| Earnings Per Share (EPS) | 1.25 |
Balance Sheet
The company has 2.74 million in cash and 24.41 million in debt, with a net cash position of -21.67 million or -4.27 per share.
| Cash & Cash Equivalents | 2.74M |
| Total Debt | 24.41M |
| Net Cash | -21.67M |
| Net Cash Per Share | -4.27 |
| Equity (Book Value) | 98.88M |
| Book Value Per Share | 19.55 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 36.50 million and capital expenditures -38.24 million, giving a free cash flow of -1.75 million.
| Operating Cash Flow | 36.50M |
| Capital Expenditures | -38.24M |
| Depreciation & Amortization | 15.55M |
| Net Borrowing | -16.83M |
| Free Cash Flow | -1.75M |
| FCF Per Share | -0.34 |
Margins
Gross margin is 43.52%, with operating and profit margins of 5.07% and 2.90%.
| Gross Margin | 43.52% |
| Operating Margin | 5.07% |
| Pretax Margin | 3.66% |
| Profit Margin | 2.90% |
| EBITDA Margin | 12.29% |
| EBIT Margin | 5.07% |
| FCF Margin | n/a |
Dividends & Yields
Beryl Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.80% |
| Shareholder Yield | 2.80% |
| Earnings Yield | 5.35% |
| FCF Yield | -1.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |